PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients ; volume:12 ; number:1 ; day:13 ; month:6 ; year:2022 ; pages:1-10 ; date:12.2022
Scientific reports ; 12, Heft 1 (13.6.2022), 1-10, 12.2022
- Creator
-
Hsu, Kuo-Hsuan
Tseng, Jeng-Sen
Yang, Tsung-Ying
Chen, Kun-Chieh
Su, Kang-Yi
Yu, Sung-Liang
Chen, Jeremy J. W.
Huang, Yen-Hsiang
Chang, Gee-Chen
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-022-13102-7
- URN
-
urn:nbn:de:101:1-2022080711580381945166
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hsu, Kuo-Hsuan
- Tseng, Jeng-Sen
- Yang, Tsung-Ying
- Chen, Kun-Chieh
- Su, Kang-Yi
- Yu, Sung-Liang
- Chen, Jeremy J. W.
- Huang, Yen-Hsiang
- Chang, Gee-Chen
- SpringerLink (Online service)
Other Objects (12)
Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC
Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status
Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Effektivität und Sicherheit des 3.-Generations-EGFR-Tyrosinkinaseinhibitors Osimertinib im unselektierten Patientenkollektiv
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells
Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC
Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status
Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Effektivität und Sicherheit des 3.-Generations-EGFR-Tyrosinkinaseinhibitors Osimertinib im unselektierten Patientenkollektiv
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells
Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC
Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status
Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Effektivität und Sicherheit des 3.-Generations-EGFR-Tyrosinkinaseinhibitors Osimertinib im unselektierten Patientenkollektiv
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M